Residency · Residency · Nephrology

Sodium and Water Homeostasis

Introduction

Total body water comprises approximately 60 percent of lean body weight in men and 50 percent in women, representing the single largest constituent of the human body. Sodium is the principal extracellular cation and the primary determinant of extracellular fluid volume, while water balance determines serum osmolality. These two regulatory systems -- water balance and sodium balance -- are governed by distinct but interacting physiologic mechanisms. The antidiuretic hormone-thirst axis regulates water balance and serum osmolality, while the renin-angiotensin-aldosterone system and natriuretic peptides regulate sodium balance and extracellular fluid volume. A thorough understanding of these mechanisms is essential for the diagnosis and management of dysnatremias, edematous states, and volume disorders encountered in clinical nephrology.

Body Fluid Compartments

Distribution of Total Body Water

Total body water is distributed between two major compartments. The intracellular fluid compartment contains approximately two-thirds of TBW, or about 28 liters in a 70-kilogram male. The extracellular fluid compartment contains the remaining one-third, approximately 14 liters, and is further subdivided into the interstitial fluid (about three-quarters of ECF, or 10.5 liters) and the plasma volume (about one-quarter of ECF, or 3.5 liters). A small transcellular fluid compartment, encompassing cerebrospinal fluid, synovial fluid, peritoneal fluid, and pleural fluid, accounts for approximately 1 to 2 liters under normal conditions.

Effective Osmoles and Tonicity

Plasma osmolality is calculated using the formula: 2 times the sodium concentration plus the glucose concentration divided by 18 plus the blood urea nitrogen divided by 2.8, with the normal range being 275 to 295 mOsm/kg. However, not all osmoles are equally effective in driving water movement across cell membranes. Tonicity, or effective osmolality, excludes freely permeable solutes such as urea and ethanol that cross cell membranes readily and therefore do not create a sustained osmotic gradient. Effective osmolality is calculated as 2 times the sodium concentration plus glucose divided by 18. Urea, despite contributing to measured osmolality, crosses cell membranes freely via urea transporters and does not drive water shifts between compartments. Glucose behaves as an effective osmole only in insulin-deficient states, where it cannot enter cells and therefore draws water from the intracellular to the extracellular space. The corrected sodium formula accounts for this phenomenon: for every 100 mg/dL increase in glucose above 100 mg/dL, the measured serum sodium should be adjusted upward by 1.6 mEq/L.

Osmotic Equilibrium

Water moves freely across most cell membranes through aquaporin channels, and at steady state the osmolality of the intracellular and extracellular compartments is equal. When the extracellular tonicity changes acutely, water shifts occur between compartments to restore osmotic equilibrium. Hypotonicity drives water into cells, causing cellular swelling, and in the brain this manifests as cerebral edema with the risk of herniation. Hypertonicity draws water out of cells, causing cellular shrinkage and brain dehydration. These osmotically driven water shifts are the fundamental basis for the clinical manifestations of dysnatremias.

<image>Diagram of body fluid compartments showing intracellular fluid, interstitial fluid, and plasma volume with their approximate volumes in a 70 kg adult. Include bidirectional arrows showing water movement governed by osmotic forces between ICF and ECF, and Starling forces between plasma and interstitial fluid. Show the key solutes in each compartment: potassium and organic phosphates intracellularly; sodium, chloride, and bicarbonate extracellularly. Include the capillary endothelium and cell membrane as barriers with aquaporin channels depicted.</image>

Sodium Handling Along the Nephron

Proximal Convoluted Tubule (PCT)

The proximal convoluted tubule is responsible for reabsorbing approximately 65 to 70 percent of filtered sodium, making it the single most important site for bulk sodium recovery. The primary apical transporter is the sodium-hydrogen exchanger NHE3, which exchanges one luminal sodium ion for one intracellular hydrogen ion. On the basolateral membrane, the sodium-potassium ATPase maintains the intracellular sodium gradient that drives NHE3 activity. Sodium reabsorption in the proximal tubule is tightly coupled to the reabsorption of bicarbonate, glucose (via SGLT2 and SGLT1), amino acids, and phosphate. SGLT2 inhibitors such as empagliflozin and dapagliflozin block 30 to 50 percent of proximal glucose and sodium reabsorption, with profound downstream effects on tubuloglomerular feedback and natriuresis. Angiotensin II stimulates NHE3 activity, thereby enhancing proximal sodium reabsorption in states of RAAS activation. Carbonic anhydrase inhibitors such as acetazolamide impair bicarbonate-linked sodium reabsorption in this segment.

Loop of Henle

The loop of Henle is responsible for approximately 25 to 30 percent of filtered sodium reabsorption, primarily in the thick ascending limb. The thin descending limb is permeable to water but relatively impermeable to sodium chloride, allowing water to be extracted as the tubular fluid descends into the increasingly hyperosmolar medullary interstitium. The thin ascending limb is permeable to sodium chloride but impermeable to water. The thick ascending limb reabsorbs sodium via the apical NKCC2 cotransporter, which simultaneously transports one sodium, one potassium, and two chloride ions from the lumen into the cell. Loop diuretics including furosemide, bumetanide, and torsemide exert their effect by blocking NKCC2. The activity of NKCC2, combined with apical potassium recycling through ROMK channels, generates a lumen-positive transepithelial voltage that drives paracellular reabsorption of calcium and magnesium. Bartter syndrome, a genetic tubulopathy mimicking chronic loop diuretic use, results from loss-of-function mutations in several components of this transport system: NKCC2 (type I), ROMK (type II), ClC-Kb (type III), barttin (type IV), or gain-of-function mutations in the calcium-sensing receptor (type V).

Distal Convoluted Tubule (DCT)

The distal convoluted tubule reabsorbs approximately 5 to 7 percent of filtered sodium through the apical sodium-chloride cotransporter NCC. Thiazide diuretics inhibit NCC and are therefore most active at this site. Gitelman syndrome results from loss-of-function mutations in NCC (encoded by the SLC12A3 gene) and produces a clinical phenotype of hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria -- essentially mimicking chronic thiazide use. The DCT is also the principal site of active transcellular calcium reabsorption, mediated by the apical TRPV5 calcium channel and the intracellular calcium-binding protein calbindin-D28K.

Collecting Duct

The collecting duct is the final site of regulated sodium reabsorption, accounting for approximately 2 to 3 percent of filtered sodium under normal conditions. Principal cells in the collecting duct express the epithelial sodium channel ENaC on their apical membrane, and sodium reabsorption through ENaC is stimulated by aldosterone, which increases both the expression and activity of ENaC. Potassium-sparing diuretics amiloride and triamterene directly block ENaC. Liddle syndrome, caused by gain-of-function mutations in ENaC subunits, produces constitutive sodium reabsorption, volume expansion, hypertension, and hypokalemia. Pseudohypoaldosteronism type 1 results from loss-of-function ENaC mutations and presents with salt wasting, hyperkalemia, and hypotension. Intercalated cells in the collecting duct serve acid-base regulatory functions: type A cells secrete hydrogen ions, while type B cells secrete bicarbonate.

<image>Cross-sectional schematic of the nephron showing each segment (proximal tubule, thin descending limb, thin ascending limb, thick ascending limb, distal convoluted tubule, connecting tubule, and collecting duct) with their respective sodium transporters labeled on the apical membrane: NHE3 and SGLT2 in the PCT, NKCC2 in the TAL, NCC in the DCT, and ENaC in the collecting duct. Show the basolateral Na-K-ATPase in all segments. Include the site of action of each diuretic class (acetazolamide, loop diuretics, thiazides, amiloride/triamterene, spironolactone) with color-coded arrows. Show the percentage of sodium reabsorbed at each segment.</image>

Water Handling and the Countercurrent System

Countercurrent Multiplication

The thick ascending limb of the loop of Henle serves as the diluting segment of the nephron, actively reabsorbing sodium chloride without water and thereby diluting the tubular fluid while concentrating the medullary interstitium. This process is the engine of countercurrent multiplication, generating the corticomedullary osmolar gradient that ranges from approximately 300 mOsm/kg at the corticomedullary junction to approximately 1200 mOsm/kg at the papillary tip. Urea recycling contributes approximately 50 percent of the inner medullary osmolality. Urea is reabsorbed from the inner medullary collecting duct into the interstitium via the urea transporters UT-A1 and UT-A3, and this urea accumulation in the medullary interstitium is essential for maximal urinary concentrating ability.

Countercurrent Exchange (Vasa Recta)

The vasa recta function as countercurrent exchangers that preserve the medullary osmolar gradient while still permitting blood flow to the medullary tissue. In the descending limb, water leaves and solute enters the vasa recta as blood flows into the increasingly hyperosmolar medulla. In the ascending limb, the reverse occurs, with water entering and solute leaving the vasa recta. This exchange prevents the washout of the medullary gradient that would occur if blood simply flowed through the medulla without equilibration. When medullary blood flow increases substantially, as during volume expansion, the gradient is partially washed out and urinary concentrating ability is impaired.

Aquaporins and ADH

Aquaporin water channels are the molecular basis of regulated water reabsorption. AQP1 is constitutively expressed in the proximal convoluted tubule and thin descending limb of the loop of Henle, where it mediates the bulk reabsorption of filtered water. AQP2, the critical regulated water channel, is inserted into the apical membrane of collecting duct principal cells in response to antidiuretic hormone. AQP3 and AQP4 are constitutively expressed on the basolateral membrane of collecting duct cells, providing the exit pathway for reabsorbed water. ADH, or vasopressin, binds to V2 receptors on the basolateral membrane of collecting duct principal cells, activating adenylyl cyclase and increasing intracellular cyclic AMP, which in turn activates protein kinase A and triggers the insertion of AQP2-containing vesicles into the apical membrane. Vasopressin V2 receptor antagonists, including tolvaptan and conivaptan, promote aquaresis -- the excretion of solute-free water -- without natriuresis.

Urine Concentration and Dilution

Maximum urinary concentrating ability, approximately 1200 mOsm/kg, requires an intact countercurrent multiplication system, adequate ADH secretion, and a responsive collecting duct. Maximum urinary dilution, approximately 50 mOsm/kg, requires an intact diluting segment (thick ascending limb and distal convoluted tubule) and complete suppression of ADH. Free water clearance, calculated as urine volume minus osmolal clearance, indicates whether the kidney is generating dilute or concentrated urine. Electrolyte-free water clearance, calculated as urine volume multiplied by (1 minus the ratio of urine sodium plus urine potassium to plasma sodium), is more clinically relevant for predicting changes in serum sodium and is the preferred tool for managing dysnatremias.

ADH Physiology

Regulation of ADH Secretion

ADH secretion is regulated by both osmotic and non-osmotic stimuli. Osmoreceptors located in the organum vasculosum of the lamina terminalis and the subfornical organ, circumventricular organs that lack a blood-brain barrier, sense changes in plasma osmolality. The threshold for ADH release is approximately 280 to 285 mOsm/kg, and above this threshold, ADH rises linearly with increasing plasma osmolality. The threshold for thirst, which provides the complementary defense against hyperosmolality, is slightly higher at approximately 290 to 295 mOsm/kg. Non-osmotic stimuli can override osmotic regulation and include effective arterial blood volume depletion sensed by carotid baroreceptors, aortic arch baroreceptors, and atrial stretch receptors. Pain, nausea, stress, hypoglycemia, and various drugs including selective serotonin reuptake inhibitors, carbamazepine, and cyclophosphamide are potent non-osmotic stimulants of ADH release. Critically, volume depletion stimulates ADH secretion even when plasma osmolality is low, explaining the pathogenesis of hyponatremia in volume-depleted states.

Pathologic ADH States

The syndrome of inappropriate antidiuretic hormone secretion, or SIADH, is characterized by ADH secretion that is inappropriate relative to the prevailing low plasma osmolality and euvolemic or hypervolemic state. Diabetes insipidus represents the opposite end of the spectrum and may be central, resulting from inadequate ADH production by the hypothalamus or posterior pituitary, or nephrogenic, resulting from renal resistance to the action of ADH. Gestational diabetes insipidus is a unique entity caused by placental vasopressinase activity that degrades endogenous ADH and is treated with desmopressin, which is resistant to enzymatic degradation.

Volume Regulation

Volume Sensors

The body detects changes in circulatory volume through high-pressure baroreceptors in the carotid sinus, aortic arch, and juxtaglomerular apparatus, as well as low-pressure baroreceptors in the atrial walls and pulmonary vasculature. The concept of effective arterial blood volume is central to understanding sodium homeostasis. EABV refers to the volume that is effectively perfusing the tissues and stimulating volume sensors, as opposed to the total circulating volume. In conditions such as congestive heart failure, hepatic cirrhosis, and nephrotic syndrome, total body sodium is markedly increased, yet the effective arterial blood volume is reduced because of poor cardiac output, splanchnic vasodilation, or decreased oncotic pressure. This reduction in EABV triggers avid sodium retention through RAAS and sympathetic activation, paradoxically worsening total body sodium overload.

Effector Mechanisms

Multiple effector systems translate changes in sensed volume into renal sodium handling. RAAS activation promotes sodium retention, potassium excretion, and systemic vasoconstriction. Sympathetic nervous system activation causes renal vasoconstriction, stimulates renin release, and enhances proximal tubular sodium reabsorption. ADH, acting through V2 receptors, promotes water retention, and through V1a receptors, produces vasoconstriction. Natriuretic peptides, including atrial natriuretic peptide and B-type natriuretic peptide released from cardiac myocytes in response to stretch, promote natriuresis, vasodilation, and suppression of the RAAS. Pressure natriuresis, the direct relationship between renal perfusion pressure and sodium excretion, provides an additional mechanism but is impaired in hypertensive states.

Edema Formation

Starling Forces at the Capillary

Edema occurs when the net fluid movement from the plasma compartment to the interstitium exceeds the capacity of the lymphatic system to return fluid to the circulation. This imbalance can result from increased capillary hydrostatic pressure, as in congestive heart failure or venous obstruction; decreased plasma oncotic pressure, as in nephrotic syndrome, cirrhosis, or malnutrition; increased capillary permeability, as in sepsis, anaphylaxis, or burns; or lymphatic obstruction, as in filariasis, post-surgical states, or malignancy.

Approach to the Edematous Patient

The clinical evaluation of the edematous patient begins with assessment of volume status through examination of jugular venous pressure, peripheral edema distribution, pulmonary congestion, and weight trends. A urine sodium concentration less than 20 mEq/L suggests avid renal sodium retention, typically reflecting secondary hyperaldosteronism. Treatment of edema generally involves sodium restriction to less than 2 grams per day, diuretic therapy targeted to the appropriate nephron segment, and disease-specific interventions. Diuretic resistance should prompt assessment of medication adherence, dietary sodium intake, renal function, the "braking phenomenon" (whereby chronic diuretic use triggers compensatory sodium avidity in untargeted nephron segments), and post-diuretic sodium retention during the interdose interval.

<image>Clinical algorithm for evaluating a patient with edema. Start with assessment of volume status (JVP, edema, lung exam). Branch into increased capillary hydrostatic pressure (CHF, venous insufficiency), decreased oncotic pressure (nephrotic syndrome, cirrhosis, malnutrition), and increased capillary permeability (sepsis, inflammation). For each branch, list key laboratory findings including urine sodium, serum albumin, BNP, and liver function tests. Include a treatment pathway showing sodium restriction, diuretic therapy with escalation strategy (loop diuretic alone, then add thiazide for sequential nephron blockade, then add metolazone or acetazolamide).</image>

Key Clinical Pearls

• Serum sodium reflects water balance, not sodium balance; hyponatremia is almost always a disorder of water excess relative to sodium, not sodium deficiency
• Effective arterial blood volume (EABV) is the key concept explaining why CHF and cirrhosis patients retain sodium despite total body sodium overload
• Electrolyte-free water clearance is more useful than free water clearance for predicting changes in serum sodium
• The "triple whammy" combination of ACEi/ARB + diuretic + NSAID dramatically increases AKI risk by simultaneously reducing RBF (NSAID), efferent arteriolar tone (ACEi/ARB), and ECF volume (diuretic)
• SGLT2 inhibitors produce natriuresis and osmotic diuresis primarily from the proximal tubule, with beneficial effects on tubuloglomerular feedback and reduction of intraglomerular pressure

References

1. Sands JM, Layton HE. The Physiology of Urinary Concentration: An Update. Semin Nephrol. 2009;29(3):178-195.
2. Ellison DH, Berl T. The Syndrome of Inappropriate Antidiuresis. N Engl J Med. 2007;356(20):2064-2072.
3. Palmer BF, Clegg DJ. Electrolyte and Acid-Base Disturbances in Patients with Diabetes Mellitus. N Engl J Med. 2015;373(6):548-559.
4. Schrier RW. Body Fluid Volume Regulation in Health and Disease: A Unifying Hypothesis. Ann Intern Med. 1990;113(2):155-159.
5. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion. Eur Heart J. 2019;40(33):2785-2803.

Read this lecture as Markdown